Anti-Tat and anti-HIV activities of trimers of n-alkylglycines

Biochemical Pharmacology

Volumn 71, Issue 5, 2006, Pages 596-604

  Márquez, Nieves ^a   Sancho, Rocío ^a   Macho, Antonio ^a   Moure, Alejandra ^b   Masip, Isabel ^b   Messeguer, Angel ^b   Muñoz, Eduardo ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b DEPARTMENT OF ENVIRONMENTAL CHEMISTRY   (Spain)

Author keywords

CDK; Combinatorial libraries; HIV 1; LTR; Peptoids; Tat

Indexed keywords

[[N [2 (2',4' DICHLOROPHENYL)ETHYL]GLYCYL] [N (2 PHENYLETHYL)GLYCYL] [N [2 (2',4' DICHLOROPHENYL)ETHYL]GLYCINAMIDE]; [[N [2 (2',4' DICHLOROPHENYL)ETHYL]GLYCYL] [N [2 (4' FLUOROROPHENYL)ETHYL]GLYCYL] [N [2 (2',4' DICHLOROPHENYL)ETHYL]GLYCINAMIDE]; [[N [2 (4' FLUOROROPHENYL)ETHYL]GLYCYL] [N (2 PHENYLETHYL)GLYCYL] [N [2 (2',4' DICHLOROPHENYL)ETHYL]GLYCINAMIDE]; [[N [2 (4' FLUOROROPHENYL)ETHYL]GLYCYL] [N (2 PHENYLETHYL)GLYCYL] [N [3,3 (DIPHENYL)PROPYL]GLYCINAMIDE]; [[N [2 (4' FLUOROROPHENYL)ETHYL]GLYCYL] [N [2 (4' FLUOROROPHENYL)ETHYL]GLYCYL] [N [2 (2',4' DICHLOROPHENYL)ETHYL]GLYCINAMIDE]; LUCIFERASE; N TRIALKYLGLYCINE DERIVATIVE; PEPTOID; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; LYMPHOID CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN RNA BINDING; T LYMPHOCYTE; TRANSACTIVATION; VIRUS TRANSCRIPTION;

ANTI-HIV AGENTS; BASE SEQUENCE; COMBINATORIAL CHEMISTRY TECHNIQUES; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE PRODUCTS, TAT; GLYCINE; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; JURKAT CELLS; MOLECULAR STRUCTURE; POLYMERS;

EID: 31044449708     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.11.024     Document Type: Article

References (42)

1. A.D. Frankel, and J.A. Young HIV-1: fifteen proteins and an RNA Annu Rev Biochem 67 1998 1 25
2. S. Nisole, and A. Saib Early steps of retrovirus replicative cycle Retrovirology 1 1 2004 9
3. R.B. Gaynor Regulation of HIV-1 gene expression by the transactivator protein Tat Curr Top Microbiol Immunol 193 1995 51 77
4. L.A. Pereira, K. Bentley, A. Peeters, M.J. Churchill, and N.J. Deacon A compilation of cellular transcription factor interactions with the HIV-1-LTR promoter Nucleic Acids Res 28 3 2000 663 668
5. J. Hauber, and B.R. Cullen Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat J Virol 62 3 1988 673 679
6. R.F. Chun, and K.T. Jeang Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus I and HIV-1 J Biol Chem 271 44 1996 27888 27894
7. P. Wei, M.E. Garber, S.M. Fang, W.H. Fischer, and K.A. Jones A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA Cell 92 4 1998 451 462
8. M. Zhou, S. Nekhai, D.C. Bharucha, A. Kumar, H. Ge, and D.H. Price TFIIH inhibits CDK9 phosphorylation during human immunodeficiency virus type 1 transcription J Biol Chem 276 48 2001 44633 44640
9. Y. Zhu, T. Pe'ery, J. Peng, Y. Ramanathan, N. Marshall, and T. Marshall Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro Genes Dev 11 20 1997 2622 2632
10. H.S. Mancebo, G. Lee, J. Flygare, J. Tomassini, P. Luu, and Y. Zhu P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro Genes Dev 11 20 1997 2633 2644
11. C. Zhou, and T.M. Rana A bimolecular mechanism of HIV-1 Tat protein interaction with RNA polymerase II transcription elongation complexes J Mol Biol 320 5 2002 925 942
12. P.G. Yeni, S.M. Hammer, C.C. Carpenter, D.A. Cooper, M.A. Fischl, and J.M. Gatell Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel J Am Med Assoc 288 2 2002 222 235
13. R.G. Ptak HIV-1 regulatory proteins: targets for novel drug development Expert Opin Investig Drugs 11 8 2000 1099 1115
14. E. De Clercq Strategies in the design of antiviral drugs Nat Rev Drug Discov 1 1 2002 13 25
15. L.M. Mansky Le Rouzic E, Benichou S and Gajary LC, Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies J Virol 77 3 2003 2071 2080
16. H.Y. Mei, M. Cui, A. Heldsinger, S.M. Lemrow, J.A. Loo, and K.A. Sannes-Lowery Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules Biochemistry 37 40 1998 14204 14212
17. B.A. Sullenger, H.F. Gallardo, G.E. Ungers, and E. Gilboa Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation J Virol 65 12 1991 6811 6816
18. F. Hamy, V. Brondani, A. Florsheimer, W. Stark, M.J. Blommers, and T. Klimkait A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition Biochemistry 37 15 1998 5086 5095
19. M.L. Zapp, S. Stern, and M.R. Green Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production Cell 74 6 1993 969 978
20. K.E. Lind, Z. Du, K. Fujinaga, B.M. Peterlin, and T.L. James Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA Chem Biol 9 2 2002 185 193
21. S.M. Miller, R.J. Simon, S. Ng, R.N. Zuckermann, J.M. Kerr, and W.H. Moos Proteolytic studies of homologous peptide and N-substituted glycine peptoid oligomers Bioorg Med Chem Lett 4 1994 2657 2662
22. J.A. Gibbons, A.A. Hancock, C.R. Vitt, S. Knepper, S.A. Buckner, and M.E. Brune Pharmacologic characterization of CHIR 2279 an N-substituted glycine peptoid with high-affinity binding for alpha 1-adrenoceptors J Pharmacol Exp Ther 277 2 1996 885 899
23. G. Heizmann, P. Hildebrand, H. Tanner, S. Ketterer, A. Pansky, and S. Froidevaux A combinatorial peptoid library for the identification of novel MSH and GRP/bombesin receptor ligands J Recept Signal Transduct Res 19 1-4 1999 449 466
24. P.G. Alluri, M.M. Reddy, K. Bachhawat-Sikder, H.J. Olivos, and T. Kodadek Isolation of protein ligands from large peptoid libraries J Am Chem Soc 125 46 2003 13995 14004
25. D. Daelemans, D. Schols, M. Witvrouw, C. Pannecouque, S. Hatse, and S. van Dooren A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry Mol Pharmacol 57 1 2000 116 124
26. F. Hamy, E.R. Felder, G. Heizmann, J. Lazdins, F. Aboul-ela, and G. Varani An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication Proc Natl Acad Sci USA 94 8 1997 3548 3553
27. J.E. Murphy, T. Uno, J.D. Hamer, F.E. Cohen, V. Dwarki, and R.N. Zuckermann A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery Proc Natl Acad Sci USA 95 4 1998 1517 1522
28. M. Humet, T. Carbonell, I. Masip, F. Sanchez-Baeza, P. Mora, and E. Canton A positional scanning combinatorial library of peptoids as a source of biological active molecules: identification of antimicrobials J Comb Chem 5 5 2003 597 605
29. C. Montoliu, M. Humet, J.J. Canales, J. Burda, R. Planells-Cases, and F. Sanchez-Baeza Prevention of in vivo excitotoxicity by a family of trialkylglycines, a novel class of neuroprotectants J Pharmacol Exp Ther 301 1 2002 29 36
30. R. Planells-Cases, C. Montoliu, M. Humet, A.M. Fernandez, C. Garcia-Martinez, and E. Valera A novel N-methyl-d-aspartate receptor open channel blocker with in vivo neuroprotectant activity J Pharmacol Exp Ther 302 1 2002 163 173
31. I. Masip, N. Cortes, M.J. Abad, M. Guardiola, E. Perez-Paya, and J. Ferragut Design and synthesis of an optimized positional scanning library of peptoids: identification of novel multidrug resistance reversal agents Bioorg Med Chem 13 6 2005 1923 1929
32. M.J. Abad-Merin, N. Cortes, I. Masip, E. Perez-Paya, J.A. Ferragut, and A. Messeguer Trimers of N-alkylglycines are potent modulators of the multidrug resistance phenotype J Pharmacol Exp Ther 313 1 2005 112 120
33. R. Sancho, M. Medarde, S. Sanchez-Palomino, B.M. Madrigal, J. Alcami, and E. Muñoz Anti-HIV activity of some lignanolides and intermediates Bioorg Med Chem Lett 14 17 2004 4483 4486
34. N. Marquez, R. Sancho, A. Macho, M.A. Calzado, B.L. Fiebich, and E. Munoz Caffeic acid phenethyl ester inhibits T-cell activation by targeting both nuclear factor of activated T-cells and NF-kappaB transcription factors J Pharmacol Exp Ther 308 3 2004 993 1001
35. R.I. Connor, B.K. Chen, S. Choe, and N.R. Landau Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes Virology 206 2 1995 935 944
36. L. Deng, T. Ammosova, A. Pumfery, F. Kashanchi, and S. Nekhai HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter J Biol Chem 277 37 2002 33922 33929
37. C. Garcia-Martinez, M. Humet, R. Planells-Cases, A. Gomis, M. Caprini, and F. Viana Attenuation of thermal nociception and hyperalgesia by VR1 blockers Proc Natl Acad Sci USA 99 4 2002 2374 2379
38. M. Canki, J.N. Thai, W. Chao, A. Ghorpade, M.J. Potash, and D.J. Volsky Highly productive infection with pseudotyped human immunodeficiency virus type 1 (HIV-1) indicates no intracellular restrictions to HIV-1 replication in primary human astrocytes J Virol 75 17 2001 7925 7933
39. M.R. Sadaie, R. Mayner, and J. Doniger A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics Antiviral Res 61 1 2004 1 18
40. N.E. Faulkner, B.R. Lane, P.J. Bock, and D.M. Markovitz Protein phosphatase 2A enhances activation of human immunodeficiency virus type 1 by phorbol myristate acetate J. Virol 77 3 2003 2276 2281
41. C.G. Newton Molecular diversity in drug design 1999 Kluwer New York 23-42
42. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Fenney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Res 23 1997 3 25